- Home
- BEKE vs BIIB Comparison
BEKE vs BIIB Comparison
Compare BEKE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEKE
- BIIB
- Stock Information
- Founded
- BEKE 2001
- BIIB 1978
- Country
- BEKE China
- BIIB United States
- Employees
- BEKE N/A
- BIIB N/A
- Industry
- BEKE Real Estate
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BEKE Finance
- BIIB Health Care
- Exchange
- BEKE Nasdaq
- BIIB Nasdaq
- Market Cap
- BEKE 22.4B
- BIIB 18.7B
- IPO Year
- BEKE 2020
- BIIB 1991
- Fundamental
- Price
- BEKE $20.07
- BIIB $144.86
- Analyst Decision
- BEKE Strong Buy
- BIIB Buy
- Analyst Count
- BEKE 6
- BIIB 27
- Target Price
- BEKE $24.97
- BIIB $188.09
- AVG Volume (30 Days)
- BEKE 6.3M
- BIIB 1.5M
- Earning Date
- BEKE 08-26-2025
- BIIB 10-29-2025
- Dividend Yield
- BEKE 1.79%
- BIIB N/A
- EPS Growth
- BEKE N/A
- BIIB 31.67
- EPS
- BEKE 0.46
- BIIB 10.45
- Revenue
- BEKE $14,384,647,393.00
- BIIB $9,997,000,000.00
- Revenue This Year
- BEKE $16.76
- BIIB $2.00
- Revenue Next Year
- BEKE $12.40
- BIIB N/A
- P/E Ratio
- BEKE $43.58
- BIIB $13.86
- Revenue Growth
- BEKE 32.52
- BIIB 3.36
- 52 Week Low
- BEKE $13.28
- BIIB $110.04
- 52 Week High
- BEKE $26.05
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- BEKE 68.52
- BIIB 60.92
- Support Level
- BEKE $17.45
- BIIB $139.54
- Resistance Level
- BEKE $20.30
- BIIB $143.74
- Average True Range (ATR)
- BEKE 0.52
- BIIB 4.32
- MACD
- BEKE 0.23
- BIIB 0.69
- Stochastic Oscillator
- BEKE 91.03
- BIIB 71.89
About BEKE KE Holdings Inc (each representing three)
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.